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Abstract
Background/ Aims: Since the reversible
phosphorylation of tyrosyl residues is a critical event
in cellular signaling pathways activated by
erythropoietin (Epo), attention has been focused on
protein tyrosine phosphatases (PTPs) and their
coordinated action with protein tyrosine kinases. The
prototypic member of the PTP family is PTP1B, a
widely expressed non-receptor PTP located both in
cytosol and intracellular membranes via its
hydrophobic C-terminal targeting sequence. PTP1B
has been implicated in the regulation of signaling
pathways involving tyrosine phosphorylation induced
by growth factors, cytokines, and hormones, such as
the downregulation of erythropoietin and insulin
receptors. However, little is known about which factor
modulates the activity of this enzyme. Methods: The
effect of Epo on PTP1B expression was studied in
the UT-7 Epo-dependent cell line. PTP1B expression
was analyzed under different conditions by Real-Time
PCR and Western blot, while PTP1B phosphatase
activity was determined by a p-nitrophenylphosphate
hydrolysis assay. Results: Epo rapidly induced an
increased expression of PTP1B which was associated
with higher PTP1B tyrosine phosphorylation and
phosphatase activity. The action of Epo on PTP1B
induction involved Janus Kinase 2 (JAK2) and
Phosphatidylinositol-3 kinase (PI3K). Conclusion: The
results allow us to suggest for the first time that,
besides modulating Epo/Epo receptor signaling,
PTP1B undergoes feedback regulation by Epo.
Introduction
The phosphorylation of tyrosyl residues in proteins
is a critical event in many signaling pathways involved in
proliferation, differentiation, and cellular response to
extrinsic factors [1]. Since protein tyrosine
phosphorylation is closely controlled by both protein
tyrosine kinases (PTKs) and tyrosine phosphatases
(PTPs), a disturbance of the balance between the activity
of these enzymes leads to abnormal tyrosine
phosphorylation which might be related to different human
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pathologies, such as cancer, diabetes, or inflammatory
diseases [2-5].
The prototype of the PTPs superfamily is the widely
expressed PTP1B. This enzyme exists as a 435 aminoacid
form of 50 kDa [6], with an N-terminal catalytic domain
(PTP domain) followed by two proline-rich motifs, and is
located on the endoplasmic reticulum (ER) through a small
hydrophobic stretch found in its C-terminus [7]. Several
biochemical studies have implicated PTP1B in the
attenuation of various PTKs signaling pathways, such as
those related to the receptors of erythropoietin, insulin,
insulin-like growth factor I, epidermal growth factor and
platelet-derived growth factor [8-12].
The erythropoietin receptor (EpoR) is essential for
the regulation of proliferation, differentiation, and survival
of erythroid cells. Following ligand binding, the receptor
conformation changes [13, 14], subsequently inducing
phosphorylation and activation of the associated kinases.
Tyrosine-phosphorylated EpoR then serves as a docking
site for other signaling proteins, like JAK2 and PI3K, which
mediate the cellular response to Epo. Even though
termination of the Epo/EpoR activation pathway is mainly
attributed to the cytosolic SH-PTP1 protein [15], it has
recently been reported that PTP1B also dephosphorylates
Epo-stimulated EpoR, thus participating in the
downregulation cascade of Epo-mediated transduction
[12].
The current study was performed to clarify possible
interactions between PTP1B and activated EpoR
intracellular pathway, using the UT-7 human leukemic
cell line as an Epo-dependent cell model. The results let
us postulate the existence of reciprocal regulation
between Epo and PTP1B.
Materials and Methods
Materials
All chemicals used were of analytical grade. Bovine serum
albumin (BSA), Ly294002, AG490, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), sodium o-vanadate,
phenylmethylsulfonyl fluoride (PMSF), aprotinin, leupeptin,
and pepstatin A were obtained from Sigma-Aldrich; Iscove’s
Modified Dulbecco’s Medium (IMDM), Taq DNA polymerase,
dNTPs, and specific primers for PTP1B and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) from Invitrogen Life
Technologies; polyclonal anti-PTP1B antibody (SC-14021,
raised against aminoacids 301-435 mapping at the C-terminus
of PTP1B) from Santa Cruz Biotechnology; monoclonal anti-
PTP1B (PH-01, epitope: PTP1B active site) from Calbiochem;
policlonal anti-actin (A4700) from Sigma, monoclonal anti-
phosphotyrosine (anti-PY) antibody (P-11120) and Protein A-
agarose from BD Transduction Laboratories; Trizol Reagent
from Gibco BRL; nitrocellulose (NC) membranes (Hybond),
chemiluminiscent system kit (ECL), and Ready To Go T-Primed
First-Strand Kit from Amersham Bioscience; agarose from
Promega; ethidium bromide from Mallinckrodt; Sybr Green I
nucleic acid stain from Roche; sodium dodecylsulfate (SDS),
acrylamide, bis-acrylamide, Triton X-100, Folin-Ciocalteu’s
reagent, Tween 20, and p-nitrophenyl phosphate (pNPP) from
Merck; fetal bovine serum (FBS) (Bioser) and penicillin-
streptomycin (PAA Laboratories) from GENSA and recombinant
human erythropoietin (rhuEpo, Hemax) from Biosidus.
Cell line and culture
UT-7 cell line was kindly provided by Dr. Patrick Mayeux
(Cochin Hospital, Paris, France). Initially established from bone
marrow cells obtained from a patient with acute megakarioblastic
leukemia, this cell line shows complete growth dependence on
Epo. Stock cultures were maintained in IMDM supplemented
with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and
1 U/ml Epo, by replacement of the medium every 3-4 days [16].
Cell cultures were developed at 37°C, in an atmosphere
containing 5% CO2 and 100% humidity. Proliferation and cell
viability were evaluated by the Trypan blue exclusion test.
MTT Assay
The MTT reduction assay modified from that of Mosmann
[17] was used to assess cell viability as a measure of Ly294002
or AG490 cytotoxicity. Briefly, after cells had been subjected to
appropriate treatments in microplates, MTT was added to each
well at a final concentration of 0.5 mg/ml an the cells were
incubated for 2 h at 37°C. The medium was removed and the
pellet washed with PBS. Finally 100 µL of 0.04 M HCl in
isopropanol was added to solubilize the blue formazan product
(reduced MTT) and the absorbance was read at a 570 nm test
wavelength with a 690 nm reference filter (Microplate Reader
BioRad, Model 680).
Precipitacion and Western Blotting
Cells were washed with ice-cold phosphate buffer saline
(PBS) containing 1 mM sodium o-vanadate and lysed on ice-
cold hypotonic lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
1% Triton X-100), with 1 mM PMSF, 1 μg/ml aprotinin, 2 μg/ml
leupeptin, 1.37 µg/ml pepstatin A, in a ratio of 200 μl to 107 cells.
After 30 min-incubation on ice, cell lysates were clarified by
centrifugation for 15 min at 15,000 g at 4°C. Total proteins were
quantified by the Lowry’s method [18].
Monoclonal anti-PTP1B antibody (epitope: active site,
Calbiochem) was added at 2 μg/ml final concentration and
incubated at 4°C for 60 min with gentle agitation. Protein A-
agarose was added and after an overnight incubation with
rotation at 4°C, immunocomplexes were collected by
centrifugation at 15,000 g for 15 min and washed twice with the
lysis buffer.
Immunoprecipitates or cell lysates corresponding to 100
µg of total proteins were boiled for 3 min in the Laemmli sample
buffer [19], fractionated on 12% polyacrilamide-SDS gel and
electrophoretically transferred to nitrocellulose membrane
during 1.5 h (transfer buffer: pH 8.3, 25 mM Tris, 195 mM glycine,
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0.05% SDS, and 20% (v/v) methanol). The membranes were
blocked by 1 h-incubation in TBS (25 mM Tris, 137 mM NaCl, 3
mM KCl, pH 7.4) containing 0.1% Tween 20 and 0.5% skim-milk
powder, and then incubated with appropriate concentrations
of the specific antibody. After washing with TBS-0.1% Tween
20, the immunoblots were probed with anti-mouse horseradish
peroxidase-conjugated secondary antibody (1:1,000) for 1 h at
20°C and washed. Specific antibody signals were detected
using the enhanced chemiluminiscence system, ECL kit, and
the bands detected by using a Fujifilm Intelligent Dark Box II
(Fuji) equipment coupled to a LAS-1000 digital camera.
Anti β-actin policlonal antibody was also used in western
detection as control for sample loading variations.
Enzyme Activity Assay
Aliquots of cell lysate equivalent to 1 mg total protein
were immunoprecipitated with anti-PTP1B (epitope: Carboxyl
terminus, Santa Cruz) as indicated and immunoprecipitates
washed with PTP assay buffer (18.5 mM HEPES, pH 7.2, 7.5
mM NaCl, 1.85 mM EDTA, 5 mM DTT). The PTP activity was
measured in a 200 µl final volume by incubation at 37°C for 30
min in PTP assay buffer containing 2.4 mM pNPP. The product
absorption was determined at 415 nm in a microplate reader.
The correction for non-enzymatic hydrolysis of pNPP was
evaluated by measuring the absorbance in the absence of
enzyme.
Reverse transcriptase-polymerase chain reaction (RT-
PCR)
Total RNA was isolated by means of the Trizol Reagent,
according to Chomczynski and Sacchi [20]. RNA concentration
was estimated by measuring the optical density at 260 nm and
then, 4.5 μg RNA was reverse transcribed by using Ready-To-
Go T-Primed First-Strand Kit. An aliquot (1 µl) of a dilution of
cDNA solution (1:10) was amplified by PCR employing specific
primers for PTP1B (sense: 5´- GGGGTGTCGTCATGCTCAA-3´
and antisense: 5´-GCCATGTGGTATAGTGGAAATGT-3´) and
for the internal standard glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) [21]. PCR reactions were performed
in a Mastercycler Gradient (Eppendorf) at the following PCR
cycling conditions: an initial denaturing step at 94°C for 5 min,
28 cycles repeating 94°C for 45 s, 59.5°C for 45 s and 72°C for 45
s and a final elongation step at 72°C for 10 min. The PCR products
were analyzed by electrophoresis on 1.5% agarose gel
containing ethidium bromide. Gels were photographed and
analyzed with the ImageGauge software.
Quantitative Real-Time PCR
Real-Time PCR for PTP1B was performed in a volume of
25 µl of a mixture containig cDNA (1:10 dilution), 0.20 mM dNTPs,
specific primers at 0.25 µM (see Material and Methods), 3 mM
MgCl2, 2 U Taq DNA polymerase and 1:30,000 SYBR Green
Stain. Real-Time PCR reactions were performed in a DNA Engine
Opticon (MJ Research Inc.) and the amplification program
consisted of an initial denaturing step (94°C for 5 min), followed
by 40 cycles (each of 94°C for 45 s, 59.5°C for 45 s and 72°C for
45 s). Sample quantification was normalized to endogenous
GAPDH which was also quantified by Real-Time PCR following
the same protocol as that for PTP1B. Acquisition of the
fluorescence signal from the samples was carried out at the
end of the elongation step. Each assay included a DNA minus
control and a standard curve performed with serial dilutions of
control cDNA obtained from UT-7 cells maintained with IMDM
10% FBS and 1U/ml Epo. All samples were run in duplicate and
the experiment was repeated three times with independently
isolated RNA.
Statistics
Results are expressed as mean ± standard error (S.E.M).
Comparison among groups was carried out by the Kruskal-
Wallis one-way analysis of variance and the Mann-Whitney
U-test when corresponding. Least significant difference with
P<0.05 was considered as the criterion for statistical significance.
Results
Erythropoietin induces the expression and
activity of PTP1B
Previous reports have proved that PTP1B
participates in the downregulation of Epo-mediated signal
transduction through dephosphorylation of Epo-stimulated
EpoR [12]. To assess the influence of Epo in the
modulation of PTP1B expression, we first investigated
possible changes in the expression level of PTP1B after
UT-7 cells had been deprived and subsequently stimulated
by Epo. These cells, strongly dependent on Epo for growth
and survival, were cultured in the absence of serum and
Epo for 18 h and after this starvation period, they were
stimulated with 10 U/ml Epo (without medium change or
addition of other supplements) for different times.
Figure 1 shows the effect of Epo stimulation upon
the PTP1B expression analyzed by Real-Time PCR (A)
and Western Blotting (B). UT-7 cells cultured without
serum and the erythropoietic growth factor (t = 0) showed
low PTP1B expression at both mRNA and protein levels,
which was already increased by a 3 h-Epo stimulation
period. From this point, protein expression level was
almost constant whereas PTP1B mRNA reached its
maximum by 9 h of Epo stimulation. Finally, PTP1B
mRNA decreased to control levels (UT-7 cells maintained
with 1U/ml Epo).
PTP1B phosphatase activity, measured by the rate
of pNPP hydrolysis, was also increased by Epo stimulation
during 3h. After this point, the enzymatic activity
decreased to control levels (Fig. 2).
Regarding the percentage of viable cells, the Trypan
blue exclusion test showed no significant differences
among treatments, being the observed viability range
between 59.5% and 68.8%, throughout the period tested.
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Erythropoietin induces PTP1B phosphorylation
Since it is known that both epidermal growth factor
and insulin stimulate PTP tyrosine phosphorylation which
increases its phosphatase activity [22], it was interesting
to investigate if Epo could also modulate PTP1B tyrosine
phosphorylation. UT-7 cells were starved of serum and
Epo for 18 h and then stimulated with 10 U/ml Epo
(without medium change or addition of other supplements)
for short periods. Afterwards, cell viability was evaluated
and cell lysates were immunoprecipitated with anti-PTP1B
antibody followed by Western blot analysis with anti-PY
antibody. Figure 3 shows the expected kinetic pattern of
a transient PTP1B tyrosine phosphorylation induced by
Epo, which was already detectable by 5 min after Epo
stimulation and declined within 6 h while cell viability was
not significantly altered during the whole period.
Fig. 2. Epo modulates PTP1B activity. Cells (1x107) were treated
as described in figure 1. Total lysates were prepared and PTP1B
was immunoprecipitated with anti-PTP1B antibody. PTP1B
phosphatase activity was determined by measuring the optical
density (415 nm) of the product from the pNPP hydrolysis.
Results are reported as the percentage activity with respect to
that of control cells. Each bar represents mean value ± standard
error (n = 3). (*) Significant differences with respect to PTP1B
activity shown at t = 0 (P < 0.05).
Fig. 3. Epo induces PTP1B tyrosine phosphorylation. Cells
(1x107) were deprived of serum and Epo during 18 h. After the
starvation period, cells were stimulated with 10 U/ml Epo (+)
during 5 min, 2, 4 or 6 h, followed by cell lysis. Cells without
Epo (-) were incubated with PBS for 5 min. Whole cell extracts
were immunoprecipitated with anti-PTP1B (α-PTP1B) and
analyzed by Western blot probed with anti-phosphotyrosine
antibody (α−PY). The figure is representative of 3 separate
experiments.
Fig.1. Epo modulates PTP1B expression. Cells (1x107) were
cultured in IMDM medium without serum and rhuEpo. After 18
h starvation (t= 0 h) cells were stimulated with 10 U/ml Epo
during different periods (3, 6, 9 or 24 h). Control cells were
maintained with 1U/ml Epo during the whole assay. Total RNA
was extracted and PTP1B expression quantified by Real-Time
PCR (A). Cell lysates were also prepared and resolved by SDS-
PAGE (B). The proteins were transferred to NC membranes and
detected by immunoblotting using anti-PTP1B antibody. Each
bar represents mean value ± standard error (n = 3). Figure 1
shows representative patterns of 3 separate experiments. (*)
Significant differences with respect to t = 0 h (P < 0.01).
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Fig. 4. JAK2 is implicated in PTP1B modulation by Epo. After 18 h of Epo deprivation, UT-7 cells were incubated in the presence
of the indicated concentrations of the JAK 2 inhibitor AG490 for 5 h and subsequently stimulated with Epo for 3 h. Control cells
were maintained with 1U/ml Epo during the whole assay. Then, cDNA and total cell lysates were prepared for quantitative Real-
Time PCR (A) or qualitative RT-PCR (B) and Western blot analysis with anti-PTP1B antibody (C), respectively. Besides, an aliquot
of total lysates was immunoprecipitated with anti-PTP1B to determine PTP1B activity (D) by measuring the optical density
(415 nm) of the product from pNPP hydrolysis and reported as percentage activity relative to that of control cells. Each bar
represents mean value ± standard error (n = 3). Figure 4 shows representative patterns of 3 separate experiments. (*) Significant
differences relative to the treatments with Epo and without inhibitor (P < 0.05).
JAK2 and PI3K are involved in PTP1B
modulation by Epo
To gain insight into the role of JAK2 and PI3K
signaling in the Epo-induced PTP1B expression, assays
were carried out in the presence of AG490 and Ly294002
(Ly), known as specific JAK2 and PI3K inhibitors,
respectively. After 18 h of Epo deprivation, UT-7 cells
were incubated for 5 h in the presence of two different
concentrations of AG490 or for 1 h with different
concentrations of Ly. Then, the cells were stimulated with
10 U/ml Epo during 3 h (without medium change or
addition of other supplements in any assay). Then, total
cell lysates and cDNA were prepared for Western blot
analysis with anti-PTP1B immunoreaction and Real-Time
PCR, respectively. The MTT assay was used to detect
cytotoxic effects.
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Cells treated with either 50 or 100 µM AG490 showed
decreased PTP1B mRNA and protein levels. Moreover,
they were almost undetectable even in the presence of
the lowest dose of the JAK2 inhibitor assayed (Fig. 4A,
B and C). Similar modulation was observed upon PTP1B
enzyme activity (Fig. 4D). Regarding cell viability, the
preincubation with AG490 before Epo stimulation had no
detectable effect (Fig. 5A).
As shown in Figure 5B, MTT reduction was not
suppressed after the incubation with Ly during 1 h, and it
was even increased after Ly pretreatment followed by 3
h-stimulation with Epo. On the other hand, PTP1B
expression was negatively regulated by Ly at mRNA and
protein levels in different ways: while PTP1B mRNA
downregulation did not depend on Ly dose and was not
strong enough to decrease mRNA up to the initial level
(Fig. 6A and 6B), the decrease in PTP1B protein level
was evident in a Ly dose dependent manner (Fig. 6C).
Moreover, the level of the enzyme detected in the
presence of Ly was even lower than the one detected
Fig. 5. Incubation with AG490 or Ly does
not affect cell viability. After 18 h of Epo
deprivation, UT-7 cells were incubated in the
presence of the indicated concentrations of
AG490 for 5 h (A) or Ly for 1 h (B) and
subsequently stimulated with Epo for 3 h.
Cell viability was determined by MTT
reduction analysis measured by optical
density at 570 nm and a 690 nm reference
wavelength. Each point represents mean
value ± standard error (n = 3).
after 18 h of Epo deprivation. In addition, the in vitro
phosphatase activity underwent a similar dose-dependent
modulation (Fig. 6D).
Discussion
The phosphorylation of protein tyrosyl residues is a
key element of the signaling pathways induced by different
stimuli that regulate cellular responses such as growth,
differentiation proliferation, and metabolism. Due to the
requirement of a strictly controlled process, coordinated
actions of protein kinases and phosphatases should be
balanced.
Since phosphorylation is the activating event for the
EpoR signaling, dephosphorylation is necessary to
downregulate this activity. The distal end of the EpoR
seems to act as a negative regulatory domain in which
phosphorylated tyrosine residues are the docking sites
for the tyrosine protein phosphatases that attenuates Epo
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Fig. 6. Inhibition of PI3-kinase causes down-regulation of PTP1B expression. After 18 h of Epo deprivation, UT-7 cells were
incubated in the presence of the indicated concentrations of Ly for 1 h and subsequently stimulated with Epo for 3 h. Control cells
were maintained with 1 U/ml Epo during the whole assay. Then, cDNA and total cell lysates were prepared for quantitative Real-
Time PCR (A) or qualitative RT-PCR (B) and Western blot analysis with anti PTP1B antibody (C), respectively. Besides, an aliquot
of total lysate was immunoprecipitated with anti-PTP1B antibody to determine PTP1B activity (D) by measuring the optical
density (415 nm) from pNPP hydrolysis. Results are expressed as percentage relative to that of control cells. Each bar represents
mean value ± standard error (n = 3). (*) Significant differences with respect to the assay with Epo and without inhibitor (P < 0.05).
signaling [23]. Although much has been investigated about
mechanisms mediated by PTKs in the intracellular
pathways activated by the binding of Epo to its specific
receptor, little is known about the role of individual PTPs
in the regulation of this activity.
The target of this research was the enzyme PTP1B,
the prototypic member of the PTP family. Since its
discovery [24], continued investigation has revealed
important data about PTP1B structure, regulation, and
function. In particular, the ability of this enzyme to
antagonize insulin receptor signaling has been pointed out
[10]. The expression of PTP1B is widely modulated in
response to circumstances ranging from metabolic stress
to cellular transformation [25, 26]. Some reports showed
increased expression and/or activity of PTP1B in insulin-
resistant states and obesity [27], especially in skeletal
muscle and adipose tissue [28].
Recently, the participation of PTP1B in the
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dephosphorylation of EpoR has also been reported. In
vitro coexpression studies have shown that PTP1B can
dephosphorylate Epo-stimulated EpoR, thereby
downregulating the cascade of Epo-mediated signal
transduction [12]. Nevertheless, no information has been
reported about modulation of the PTP1B expression by
this growth factor. Based on this notion, the present study
has been designed to characterize the interaction between
PTP1B and Epo/EpoR activated intracellular pathways
in Epo-dependent cells, as well as to investigate whether
PTP1B expression is modulated by the growth factor.
The model used was the UT-7 cell line, which is an
Epo-responsive cell line co-expressing EpoR and PTP1B.
We found that Epo induced PTP1B expression which
is associated to increased PTP1B tyrosine
phosphorylation and enzyme activity. These conclusions
came from different experiments that showed an increase
in the phosphatase expression at both mRNA and protein
levels after cell stimulation by Epo. The hormone
upregulated PTP1B mRNA expression as soon as 3 hours,
increased level that peaked at 9 hours and remained
elevated for 24 hours. We then confirmed the rapid and
sustained Epo-induced upregulation of PTP1B protein by
Western blot analysis (Fig. 1B).
These findings agreed with a parallel increase in the
activity of PTP1B. When this activity was measured by
the hydrolysis of p-nitrophenylphosphate, the observed
value before Epo activation (at t=0) was not as low as
expected (Fig. 2), presumably due to the existence of
additional phosphatases precipitated by the polyclonal
antibody.
Different previous studies have shown that PTP1B
itself is a phosphoprotein. Bandyopadhyay et al [29] have
shown that insulin stimulates phosphorylation of PTP1B
on three tyrosine residues, which increased its
phosphatase activity [22]. This action creates a negative
feedback loop to downregulate insulin signaling. The
epidermal growth factor receptor also phophorylated
PTP1B on a motif flanking Tyr-66 and this phosphorylation
increased catalytic activity by near three-fold [30]. The
phosphoserine content of PTP1B was also regulated by
insulin stimulation but this modulation was found to be
associated to a decreased PTP1B activity, which created
a positive feedback mechanism for insulin signaling [31].
During mitosis, PTP1B serine residues are phosphorylated
without alteration of enzymatic activity [30]. Other protein
kinases, such as PKA or PKC, phosphorylated serine
residues of PTP1B [32] but their effects on the enzymatic
activity are not entirely clear. Based on these results, it
has been suggested that tyrosine and serine
phosphorylation might regulate PTP1B activity in a
temporal fashion depending on the stimulus and/or growth
factor involved. Our results agree with these previous
reported observations concerning tyrosine
phosphorylation. Like insulin and other growth factors,
the Epo-induced PTP1B tyrosine phosphorylation was
associated with an increase in phosphatase activity.
Opposite results were found by Sharlow E. et al [33] in a
mouse cell line in which Epo failed to modulate the
expression and tyrosine phosphorylation of hematopoietic
cell phosphatase (HCP), another phosphatase implicated
in EpoR signaling downregulation.
Thus, our findings suggest an important and different
role of PTP1B as modulator in the erythropoietic process
given that Epo is the principal hormone that regulates the
proliferation and differentiation of erythroid precursor
cells.
We also investigated the participation of downstream
mediators, such as JAK2 and PI3K in assays carried out
in the presence of AG 490 and Ly294002, known as
specific JAK2 and PI3K inhibitors, respectively. Blocking
the kinase activity of JAK2 and PI3K by their specific
inhibitors abolished the Epo-mediated increase of PTP1B
expression and partially suppressed its enzyme activity
(Fig. 4 and 6). However, a higher concentration of PI3K
inhibitor than of JAK2 inhibitor was necessary to observe
a complete PTP1B inhibition, presumably caused by the
fact that JAK2 is upstream PI3K in the Epo signaling
pathway. Thus, the AG490 and Ly294002 assays indicated
that Epo–stimulated JAK2 and PI3K appear to be
necessary for inducing PTP1B, even though different
degree of participation was observed.
Altered expression of PTP1B has been found in a
number of disease conditions associated with aberrant
tyrosine phosphorylation [22, 24 26]. In this context,
enhanced expression of PTP1B was detected in animal
models of diabetes as well as in patients with diabetes
and insulin resistance [34]. Since erythropoiesis is
regulated by a strict equilibrium between activities of both
protein tyrosine kinases and tyrosine phosphatases, an
imbalance due to a defect in phosphatase activity may
allow uncontrollable cell proliferation suggesting a possible
etiology for polycythemia vera [35]. On the other hand,
after approximately twenty years of therapy with
recombinant human erythropoietin (rhuEpo), poor
responses to the treatment are frequently observed [36].
A contributing factor to this effect may be the elevation
of PTP activity. Since PTP1B is involved in EpoR signal
attenuation, an approach to improving rhuEpo treatment
could be focused on modulation of EpoR intracellular signal
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